KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Depreciation & Amortization (CF): 2013-2025

Historic Depreciation & Amortization (CF) for Xenon Pharmaceuticals (XENE) over the last 11 years, with Sep 2025 value amounting to $641,000.

  • Xenon Pharmaceuticals' Depreciation & Amortization (CF) fell 3.90% to $641,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year increase of 105.38%. This contributed to the annual value of $2.6 million for FY2024, which is 24.21% up from last year.
  • Latest data reveals that Xenon Pharmaceuticals reported Depreciation & Amortization (CF) of $641,000 as of Q3 2025, which was up 1.42% from $632,000 recorded in Q2 2025.
  • Xenon Pharmaceuticals' 5-year Depreciation & Amortization (CF) high stood at $1.7 million for Q3 2023, and its period low was -$629,000 during Q4 2023.
  • For the 3-year period, Xenon Pharmaceuticals' Depreciation & Amortization (CF) averaged around $595,727, with its median value being $641,000 (2025).
  • The largest annual percentage gain for Xenon Pharmaceuticals' Depreciation & Amortization (CF) in the last 5 years was 384.36% (2023), contrasted with its biggest fall of 312.50% (2023).
  • Over the past 5 years, Xenon Pharmaceuticals' Depreciation & Amortization (CF) (Quarterly) stood at $270,000 in 2021, then climbed by 9.63% to $296,000 in 2022, then plummeted by 312.50% to -$629,000 in 2023, then surged by 205.88% to $666,000 in 2024, then declined by 3.90% to $641,000 in 2025.
  • Its Depreciation & Amortization (CF) stands at $641,000 for Q3 2025, versus $632,000 for Q2 2025 and $659,000 for Q1 2025.